[FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment].
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use*; D048588:Benzoxazines; D002648:Child; D002986:Clinical Trials as Topic; D000075202:Contraindications; D003521:Cyclopropanes; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D010078:Oxazines / Q000191:economics / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz
La FDA donne son approbation au premier antirétroviral VIH de DuPont Pharma: SUSTIVA* (éfavirenz) SUSTIVA* doit être associé à d'autres antirétroviraux et pourrait constituer une nouvelle alternative comme traitement de première intention.